Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Sales (2016 - 2025)

Ultragenyx Pharmaceutical has reported Return on Sales over the past 10 years, most recently at 0.01% for Q4 2025.

  • Quarterly Return on Sales changed 0.0% to 0.01% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.01% through Dec 2025, changed 0.0% year-over-year, with the annual reading at 0.01% for FY2025, 0.0% changed from the prior year.
  • Return on Sales was 0.01% for Q4 2025 at Ultragenyx Pharmaceutical, up from 0.01% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.04% in Q4 2021 and troughed at 0.03% in Q3 2022.
  • The 5-year median for Return on Sales is 0.01% (2025), against an average of 0.01%.
  • Year-over-year, Return on Sales decreased -5bps in 2022 and then rose 5bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 0.04% in 2021, then plummeted by -137bps to 0.01% in 2022, then surged by 357bps to 0.04% in 2023, then tumbled by -121bps to 0.01% in 2024, then rose by 24bps to 0.01% in 2025.
  • Per Business Quant, the three most recent readings for RARE's Return on Sales are 0.01% (Q4 2025), 0.01% (Q3 2025), and 0.01% (Q2 2025).